RCMI Coordinating Center (RCMI CC) Header Logo

Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.

Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, M?rquez-Garb?n DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support